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Background: Ageing is accompanied by reduced immunity, termed immunesenescence. The immune system does
not act in isolation and is sensitive to both psychological and physical stress. Hip fracture is a common physical
stressor in older adults with a high incidence of new onset depression, which relates to poorer prognosis. We
therefore set out to examine the possible synergistic effects of physical stress (hip fracture) and psychological stress
(depressive symptoms) on the aged immune system.
Results: T cell phenotype and function was assessed in 101 hip fracture patients (81 female) 6 weeks after hip
fracture and 43 healthy age-matched controls (26 female). 38 fracture patients had depressive symptoms at 6 weeks.
T cell frequency (p = .01) and numbers (p = .003) were both lower in depressed hip fracture patients compared to
healthy controls. The frequency of senescent CD28-ve (p = .001), CD57+ve (p = .001), KLRG1+ve (p = .03) CD8 T cells, as
well as senescent CD28-ve CD4+ve (p = .01) and CD57+ve CD4+ve (p = .003) T cells were higher in depressed hip
fracture patients compared with healthy controls and the frequency of CD28-ve CD8 T cells was also higher when
compared to patients with hip fracture alone (p = .01). Additionally, activated CD69+ve (p = .005) and HLADR+ve
(p < .001) CD8 T cells, were also higher in depressed hip fracture patients compared to healthy controls. On examining
cytokine production by activated T cells, a significant increase in TNFα (p = .03) and IL6 (p = .04) production was
observed in CD4 T cells from hip fracture patients with depressive symptoms compared to healthy controls.
Conclusions: As none of the patients in the study had a prior history of depression, our data suggest that the
development of depressive symptoms in hip fracture patients is associated with altered T cell phenotype and increased
pro-inflammatory function which is not seen in patients who do not develop depression after hip fracture. Treating
depressive symptoms promptly in hip fracture patients may therefore improve immunity and outcomes in these
patients.
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Healthy ageing is associated with a significant decline in
immune competence and ability to mount a robust
immune response, termed immunesenescence [1]. This
compromised immune response is due in large part to
extensive remodelling of the adaptive immune system
including thymic atrophy [2], a decrease in the CD4:* Correspondence: J.M.Lord@bham.ac.uk
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unless otherwise stated.CD8 ratio [3,4] and an increase in the naïve: memory
T cell ratio [4,5]. Immune ageing also includes marked
phenotypic alterations in T cells associated with func-
tional senescence, notably loss of the co-stimulatory re-
ceptor CD28 and acquisition of receptors normally
associated with Natural Killer cells, for example KLRG-1
[6]. The result is an accumulation with age of CD28-ve,
KLRG-1+ve, CD57+ve senescent T cells [7,8] as well as
activated HLADR+ve T cells [9]. Furthermore, ageing is ac-
companied by a decline in CD4 helper activity [10] and a
shift from a Th1 (IFNγ, IL2) to Th2 (IL10, IL4) phenotype
on activation [11], but an increase in pro-inflammatory
cytokine production by T cells overall [12,13].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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experience greater levels of stress, anxiousness and de-
pression than young adults [14]. Meta-analysis of the lit-
erature over the past few decades has led to the
development of the hypothesis that chronic stressful
events are suppressors of immune function [15]. Inter-
estingly, there is accumulating evidence suggesting that
the effects of stress and age are interactive with chronic
stress exacerbating the effects of ageing on immune
function [16]. Our own work has shown that innate
immunity is susceptible to the effects of stress, with neu-
trophil superoxide generation reduced in old hip fracture
patients [17] and bereaved older adults [18].
Hip fracture is a common and potentially devastating
injury in older adults [19]. 1 in 3 older adults fall each
year and it is predicted that this will result in 117,000
hip fractures by 2016 [20]. Even though hip fracture is
treatable, it is a severe physical stressor for older indivi-
duals. Medical events in older adults have been asso-
ciated with a significant risk of developing depression
[21] and a high rate of depression, ranging from 9 - 47%,
has been reported in UK and US based studies of older
adults with hip fracture [22]. Importantly, depression is
associated with increased risk of infections and poor sur-
vival [23], impaired recovery and a reduced ability to re-
gain pre-fracture levels of physical functioning [24].
The hypothalamus-pituitary-adrenal (HPA) axis acts as
a pivotal regulator of the stress responses by mobilising
energy reserves and modulating immune responses [25].
Glucocorticoids (GCs) are key effectors of the HPA axis
and are potent immune suppressors. Dehydroepiandros-
terone sulphate (DHEAS), a major steroid produced by
the adrenal gland, has been reported to have anti-
depressive, anti-glucocorticoid and immune-enhancing
properties [26]. Some previous studies have suggested
that healthy ageing is accompanied by hyperactivation of
the HPA axis, especially in situations of chronic stress,
resulting in prolonged exposure to cortisol [27]. This is
due also in large part to dramatic changes in the serum
level of DHEAS which reaches peak concentrations dur-
ing the third decade of life, after which a steady decline
occurs with age (1–2% per year); such that by the age of
80, DHEAS levels have reached 10-20% of their peak
level [28]. Therefore, the current literature suggests that
ageing is accompanied by an elevated cortisol:DHEAS
ratio which may be a key factor contributing towards
age associated immune dysregulation [29] and which
might be heightened by chronic stress. In a previous
study, our group reported a raised cortisol: DHEAS ratio
in old hip fracture patients compared to comparable
young trauma patients [30]. We have also reported re-
cently that suppression of innate immunity, specifically
neutrophil function, only occurred in those hip fracture
patients that developed depressive symptoms [31].The present study sought to test the hypothesis that
psychological distress, specifically depressive symptoms,
would act additively with the physical stress of hip fracture
to amplify the effect of ageing upon adaptive immunity,
with specific reference to T cells. It also examined the role
of the cortisol and pro- and anti-inflammatory cytokines
as potential mediators of any effects observed.
Results
Participant demographics
The full demographic profiles of the participants have
been reported previously [31]. Patients were classified
into two groups on the basis of their GDS scores: hip
fracture patients with a GDS score of 5 or less were clas-
sified as non-depressed (HF; hip fracture only), those
with a score of 6 or greater were categorised as having
depressive symptoms (HF + D; Hip fracture patients with
depressive symptoms). In this study we observed that 38
(37%) of the hip fracture patients had depressive symp-
toms 4–6 weeks after their fracture.
Peripheral T cell numbers in hip fracture patients
Peripheral T cells counts in hip fracture patients with and
without depressive symptoms were compared with healthy
older adults. Significant differences in percentages of
CD3+ve T cells in the PBMC pool were found between the
three groups, F (2, 101) = 4.59, p = .01, η2 = .08, [Figure 1a],
which was driven by a significant decline in percentage of
T cells in hip fracture patients with depressive symptoms
compared with healthy controls (p = .01) but not with hip
fracture patients without depressive symptoms (p = .12).
Similarly, on examining the absolute numbers of T cells in
peripheral blood, significant differences were seen bet-
ween our three groups, F (2, 51) = 7.18, p = .002, η2 = .22
[Figure 1b], with a decline shown in T cells in hip fracture
patients with depressive symptoms compared with healthy
controls (p = .003). When the above analyses were re-
peated with adjustment for age, sex and BMI, the results
remained significant (data not shown).
CD4:CD8 T cell ratio in hip fracture patients
On examining the percentage of CD4 T cells, no signifi-
cant differences were observed between our three
groups, F (2, 85) = .68, p = .50, η2 = .01 [Table 1]. How-
ever, significant differences occurred in absolute num-
bers of CD4 T cells, F (2, 52) = 6.01, p = .004, η2 = .18,
driven by a significant decline in absolute numbers of
CD4 T cells in hip fracture patients with depressive
symptoms compared with healthy controls (p = .006)
only. No significant differences were observed between
the percentage of CD8 T cells, F (2, 97) = .13, p = .87,
η2 = .003, or in absolute numbers of CD8 T cells between
our three groups, F (2, 52) = 1.31, p = .27, η2 = .04,
[Table 1]. Thus no significant differences were seen in
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Figure 1 Frequency of peripheral T lymphocytes in hip fracture patients with and without depressive symptoms versus healthy
controls. (a) The percentage of CD3+ve T cells in healthy controls: n = 37; hip fracture patients without depression (HF): n = 38 and hip fracture
patients with depressive symptoms (HF + D): n = 29.The solid bar represents the mean value. (b) The mean absolute number of T cells in healthy
controls: n = 20; hip fracture patients without depression (HF): n = 19 and hip fracture patients with depressive symptoms (HF + D): n = 15. Data
are mean ± SEM. *p < .05 and **p < .01. Representative flow cytometry plots and gating strategy of PBMCs from a young individual stained with
anti-CD3 and (c) anti-CD4, and CD8, (d) and anti-CD45RA and -CCR7 (e and f).
Table 1 Participant peripheral distribution of T cells by group
Variable Controls Mean (SD)
HF HF + D p
CD4+ve T cells (%) 65.55 (10.57) 68.97 (12.21) 67.40 (13.76) .50
Absolute numbers (106/ml) .85 (.26) .63 (.29) .55 (.22) .004
CD8+ve T cells (%) 28.31 (10.01) 26.78 (12.23) 27.32 (14.34) .87
Absolute numbers (106/ml) .32 (.22) .25 (.16) .21 (.18) .27
CD4:CD8 ratio 2.80 (1.76) 3.41 (2.98) 3.56 (2.61) .33
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1.11, p = .33, η2 = .02 [Table 1].
Memory: naive T cell ratio in hip fracture patients
CD4 T cells and CD8 T cells can be divided into four dif-
ferentiation subsets on the basis of expression of CD45RA
and CCR7: naïve, central memory (CM), effector memory
(EM) and terminally differentiated effector memory cells
(EMRA) [32]. Figures 1c-f show representative FACs plots
for PBMCs stained with anti-CD3 and anti-CD4, CD8,
CD45RA and CCR7 antibodies to identify these subsets.
On examining the percentage, F (2, 85) = .13, p = .87,
η2 = .003, and absolute numbers of naïve CD4 T cells in
peripheral blood, F (2, 51) = 2.07, p = .13, η2 = .07 no sig-
nificant differences were found between subject groups
[Table 2]. Further, on examining central memory CD4 T
cell subsets, no significant differences occurred in their
percentages, F (2,86) = .90, p = .40, η2 = .02, or absolute
numbers F (2, 51) = 1.37, p = .26, η2 = .05, between the
three groups [Table 2]. Similarly, no significant differences
were found in the percentage, F (2, 86) = .20, p = .81,
η2 = .005, or absolute numbers, F (2, 51) = .77, p = .46,
η2 = .03, of effector memory CD4 T cells [Table 2]. Finally,
no significant differences were seen in the percentage,
F (2, 86) = .23, p = .79, η2 = .005, or in absolute numbers of
effector memory RA CD4 T cells, F (2, 51) = 1.83, p = .16,
η2 = .06 [Table 2]. Thus, the naïve:memory ratio for CD4
T cells also did not significantly differ between hip fracture
patients with and without depressive symptoms and
healthy controls, F (2, 89) = .21, p = .80, η2 = .005 [Table 2].
We then examined the distribution of naïve and mem-
ory cells amongst CD8 T cells. Firstly, no differences
were observed in the percentage, F (2, 85) = .05, p = .94,
η2 = .001, or absolute numbers of naïve CD8 T cells
F (2, 51) = 1.77, p = .18, η2 = .06, between the threeTable 2 Naive and memory CD4 T lymphocytes in hip fracture
Variable Controls
Naïve CD4 T cells (%) 38.92 (19.65)
Absolute numbers (106/ml) .35 (.27)
CM CD4 T cells (%) 3.49 (6.99)
Absolute numbers (106/ml) .01 (.01)
EM CD4 T cells (%) 19.38 (10.62)
Absolute numbers (106/ml) .14 (.07)
EMRA CD4 T cells (%) 38.40 (17.15)
Absolute numbers (106/ml) .31 (.14)
Total memory CD4 T cells (%) 61.07 (19.64)
Absolute numbers (106/ml) .46 (.14)
Naive: memory ratio .82 (.87)groups [Table 3]. Further, on examining memory CD8
T cell subsets, no significant differences were observed
in the percentage, F (2,85) = 1.34, p = .26, η2 = .03, or ab-
solute numbers F (2, 51) = .80, p = .45, η2 = .03, of central
memory CD8 T cells between the three groups [Table 3].
Similarly, no significant differences were found in the per-
centage, F (2, 85) = 2.77, p = .07, η2 = .06, or absolute num-
bers of effector memory CD8 T cells, F (2, 51) = 1.21,
p = .30, η2 = .04 [Table 3] and the percentage, F (2, 85) = .55,
p = .57, η2 = .01, and absolute numbers of effector memory
RA CD8 T cells, F (2, 51) = .50, p = .60, η2 = .01, did not dif-
fer between groups [Table 3]. Thus, the naïve: memory ratio
for CD8 T cells did not significantly differ between the
three groups, F (2, 86) = .12, p = .89, η2 = .003, [Table 3].
Accumulation of senescent T cells in hip fracture patients
with depressive symptoms
CD28 is a co-stimulatory molecule involved in T cell
activation which is lost as T cells progress towards
senescence. PBMCs were stained with an anti-CD28 anti-
body to identify CD28-ve and CD28+ve cells [Figure 2a].
On examining the frequency of circulating CD28-ve CD4
T cells, we found significant differences between the three
groups, F (2, 62) = 5.26, p = .008, η2 = .14, driven by a sig-
nificant increase in the percentage of CD28-ve CD4 T cells
in hip fracture patients with depressive symptoms com-
pared with healthy controls (p = .01) and hip fracture pa-
tients without depressive symptoms (p = .04) [Figure 2b].
Similarly, differences in the frequency of circulating
CD28-ve CD8 T cells were found between the three
groups, F (2, 62) = 8.30, p = .001, η2 = .21, driven by a sig-
nificant increase in the percentage of CD28-ve CD8 T cells
in hip fracture patients with depressive symptoms com-
pared with healthy controls (p = .001) and hip fracture pa-
tients without depressive symptoms (p = .01) [Figure 2b].patients
Mean (SD)
HF HF + D p
36.87 (20.55) 36.55 (18.11) .87
.22 (.22) .21 (.15) .13
3.49 (3.37) 5.38 (6.98) .40
.03 (.02) .02 (.02) .26
20.33 (10.93) 21.39 (15.31) .81
.14 (.11) .10 (.08) .46
40.10 (17.36) 36.96 (16.42) .79
.26 (.17) .22 (.10) .16
63.16 (20.54) 63.44 (18.04) .87
.39 (.21) .34 (.15) .12
.87 (.84) .73 (.63) .80
Table 3 Naive and memory CD8 T lymphocytes in hip fracture patients
Variable Controls Mean (SD)
HF HF + D p
Naïve CD8 T cells (%) 16.98 (16.12) 15.73 (13.11) 16.61 (13.89) .94
Absolute numbers (106/ml) .05 (.07) .02 (.04) .02 (.01) .18
CM CD8 T cells (%) 26.55 (14.61) 33.17 (20.09) 32.03 (16.01) .26
Absolute numbers (106/ml) .06 (.06) .10 (.11) .09 (.09) .45
EM CD8 T cells (%) 41.04 (13.27) 33.40 (16.16) 33.56 (14.44) .07
Absolute numbers (106/ml) .13 (.09) .09 (.10) .09 (.08) .30
EMRA CD8 T cells (%) 14.44 (11.09) 17.02 (13.50) 17.63 (13.64) .57
Absolute numbers (106/ml) .04 (.04) .04 (.09) .02 (.02) .60
Total memory CD8 T cells (%) 83.01 (16.12) 83.99 (12.89) 82.43 (14.65) .92
Absolute numbers (106/ml) .27 (.20) .21 (.16) .19 (.19) .39
Naive: memory ratio .26 (.41) .23 (.26) .28 (.45) .89
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for age, sex and BMI, the results remained significant
(data not shown).
To further investigate possible increases in senescent
T cells in hip fracture patients other markers of senes-
cence were examined, such as CD57 [33]. On examining
CD57 expression [Figure 2c], we found significant diffe-
rences in CD57+ve CD4 T cells, F (2, 62) = 1.32, p = .008,
η2 = .16 between the three groups [Figure 2d], driven by
an increase in the percentage of CD57+ve T cells in
hip fracture patients with depressive symptoms com-
pared with healthy controls (p = .003). Similarly, diffe-
rences in frequency of circulating CD57+ve CD8 T cells
were seen between our three groups, F (2, 62) = 8.16,
p = .001, η2 = .20, driven by a significant increase in the
percentage of CD57+ve CD8 T cells in hip fracture pa-
tients with depressive symptoms compared with healthy
controls (p = .001) [Figure 2d]. When the above analyses
were repeated with adjustment for age, sex and BMI, the
results remained significant (data not shown).
Finally, on examining frequency of CD28-veCD57+ve
CD4 T cells significant differences, F (2, 56) = 6.28,
p = .003, η2 = .18 occurred [Additional file 1: Figure S1a],
due to increased frequency of CD28-ve CD57+ve CD4 T
cells in hip fracture patients with depressive symptoms
compared with healthy controls, p = .002, but not on
comparison with hip fracture patients without depressive
symptoms, p = .13. Similarly, the frequency of CD28-ve
CD57+ve CD8 T cells were also significantly different,
F (2, 56) = 4.12, p = .02, η2 = .12 between the three
groups [Additional file 1: Figure S1b], due to a signifi-
cant increase in frequency of CD28-ve CD57+ve CD8 T
cells in hip fracture patients with depressive symptoms
compared with healthy controls, p = .02 but not in com-
parison with hip fracture patients without depressive
symptoms, p = .49.Killer cell lectin like receptor G 1(KLRG1) has also
been identified as a marker for functional senescence in
T cells [34]. On examining KLRG1 expression on T cells
[Figure 3a], no significant differences were reported in
the frequency of KLRG1+ve CD4 T cells, F (2, 55) = 2.53,
p = .09, η2 = .08 between the three groups [Figure 3b].
However, significant differences were seen in the per-
centage of KLRG1+ve CD8 T cells between our groups,
F (2, 55) = 3.91, p = .02, η2 = .12, driven by an increase in
hip fracture patients with depressive symptoms com-
pared with healthy controls (p = .03).
Elevated levels of Programmed cell death (PD-1) recep-
tor is also a hallmark of T cell dysfunction termed T cell
exhaustion [35]. T cell exhaustion is characterised by a
loss of effector T cell function, including cytokine produc-
tion, reduced proliferation capacity and ex vivo killing
[36]. Limited studies examining PD-1 with age have re-
ported an increase in PD-1 expression on the T cells of
aged mice [37,38]. In this study we report for the first time
significant differences in peripheral PD1+ve CD4 T cells
[Figure 3c], F (2, 62) = 4.72, p = .01, η2 = .13 and peripheral
PD1+ve CD8 T cells, F (2, 62) = 3.11, p = .05, η2 = .09 bet-
ween the three groups [Figure 3d], driven by an increase
in the percentage of PD1+ve CD4 T and PD1+ve CD8
T cells in hip fracture patients with depressive symp-
toms compared with healthy controls, p = .01 and p = .05
respectively.
Accumulation of activated T cells in hip fracture patients
with depressive symptoms
The expression of different activation markers CD69
(early), CD25 (middle) and HLADR (late) on T cells was
also examined [Figure 4a]. Firstly, on examining expres-
sion of CD69 on CD4 T cells no significant differences
were observed between the three groups, F (2, 64) = 1.51,
p = .003, η2 = .16 [Figure 4b], though significant differences
0Figure 2 Frequency of peripheral senescent T lymphocytes in hip fracture patients with and without depressive symptoms versus
healthy controls. (a) Representative flow cytometry plots showing frequency of CD28+ve CD8 T cells in a healthy control, hip fracture and a hip
fracture patient with depressive symptoms. (b) The percentage of CD28-ve CD4 and CD8 T cells in healthy controls: n = 23 (open bars); hip
fracture patients without depression n = 19 (grey bars); and hip fracture patients with depressive symptoms (black bars): n = 23. Data are mean ± SEM.
*p < .05 and **p < .01. (c) Representative flow cytometry plots showing frequency of CD57+ve CD8 T cells in a healthy control, hip fracture and a hip
fracture patient with depressive symptoms. (d) The percentage of CD57+ve CD4 and CD8 T cells in healthy controls: n = 23 (open bars); hip fracture
patients without depression n = 19 (grey bars); and hip fracture patients with depressive symptoms (black bars): n = 23.
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η2 = .14, driven by an increase in the percentage of
CD69+ve CD8 T cells in hip fracture patients with
depressive symptoms compared with healthy controls
(p = .005).On examining peripheral distribution of CD25+ve CD4
T cells and CD25+ve CD8 T cells no significant diffe-
rences were found, F (2, 53) = 1.30, p = .28, η2 = .04 (data
not shown). Similarly the frequency of HLADR expres-
sing CD4 T cells [Figure 4c] was not different between
Figure 3 (See legend on next page.)
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Figure 3 Frequency of peripheral senescent and exhausted T lymphocytes in hip fracture patients with and without depressive
symptoms versus healthy controls. (a) Representative flow cytometry plots showing frequency of KLRG1+ve CD8 T cells in a healthy control,
hip fracture and a hip fracture patient with depressive symptoms. (b) The percentage of KLRG1+ve CD4 and CD8 T cells in healthy controls: n = 23
(open bars); hip fracture patients without depression n = 19 (grey bars); and hip fracture patients with depressive symptoms n = 23 (black bars).
(c) Representative flow cytometry plots showing frequency of PD1+ve CD8 T cells in a healthy control, hip fracture and a hip fracture patient with
depressive symptoms. (d) The percentage of PD1+ve CD4 and CD8 T cells in healthy controls: n = 23 (open bars); hip fracture patients without
depression n = 19 (grey bars); and hip fracture patients with depressive symptoms n = 23 (black bars). Data are mean ± SEM. *p < .05 and **p < .01.
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[Figure 4d], though we did find significant differences in
the frequency of peripheral HLADR+ve CD8 T cells,
F (2, 60) = 13.58, p < .001, η2 = .31 between our three
groups [Figure 4d], driven by an increase in the percen-
tage of HLADR+ve CD8 T cells in hip fracture patients
with depressive symptoms compared with healthy con-
trols (p < .001). When the above analyses were repeated
with adjustment for age, sex and BMI, the results still
remained significant (data not shown).
Th1/Th2/Th17 balance
To compare functional activity of T cells between
healthy controls and hip fracture patients, the balance of
IFNγ+ve (Th1): IL4+ve (Th2) and IL17+ve (Th17) CD4 T
cells was investigated post stimulation with PMA and
Ionomycin. In this study, no significant differences were
found in the Th1 / Th2 ratio between the three groups
F (2, 59) = 1.49, p = .23, η2 = .04 [Figure 5a]. The fre-
quency of IL17+ve CD4 T cells post-stimulation with
PMA and Ionomycin was not significantly different be-
tween our three groups F (2, 37) = .93, p = .40, η2 = .04
[Figure 5b]. Further, measuring circulating serum levels
of IL17, revealed no significant differences between
healthy controls and hip fracture patients with and with-
out depression F (2, 63) = .36, p = .69, η2 = .01.
Pro-inflammatory cytokine production by T cells in hip
fracture patients
On comparing the frequency of IL6+ve CD4 T cells
[Figure 5c] post-stimulation with PMA and Ionomycin,
significant differences were found between our three
groups F (2, 57) = 3.47, p = .03, η2 = .10, driven by an
increase in percentage of IL6+ve CD4 T cells in hip frac-
ture patients with depressive symptoms compared with
healthy controls, p = .04, no significant differences were
observed between hip fracture patients with and without
depressive symptoms, p = .17 [Figure 5d]. The frequency
of TNFα+ve CD4 T cells [Figure 5c] post-stimulation
with PMA and Ionomycin, showed significant diffe-
rences between our three groups F (2, 58) = 3.49, p = .03,
η2 = .10, driven by an increase in percentage of TNFα+ve
CD4 T cells in hip fracture patients with depres-
sive symptoms compared with healthy controls, p = .03
[Figure 5e].GDS scores and T cell phenotype
For several measures of T cell numbers or phenotype
there was an effect of depression not seen in patients
with hip fracture alone. To see if there was a graded as-
sociation between depressive symptoms and T cells in
these patients linear regression analysis was performed.
In relation to senescent T cells there was an association
between GDS scores and the frequency of peripheral
CD57+ve CD4 T cells, r (42) = .42 , p = .006 [Figure 6a],
though no significant association was found for CD57+ve
CD8 T cells, r (42) = .15, p = .32. There was also a trend
towards an accumulation of KLRG1+ve T cells in hip
fracture patients with higher GDS scores, but this did
not reach statistical significance for the frequency of
KLRG1+ve CD4 T cells, r (39) = .29, p = .06, or KLRG1+ve
CD8 T cells, r (39) = .28, p = .07. There was no signifi-
cant association between GDS scores and the frequency
of peripheral CD28-ve CD4 T cells, r (42) = .19, p = .22,
but there was an association between GDS scores and
peripheral CD28-ve CD8 T cells, r (42) = .30, p = .04
[Figure 6b]. There was no significant association observed
between GDS scores and the frequency of CD69+ve CD8
T cells, r (46) = .17, p = .25, or HLADR+ve CD8 T cells,
r (42) = .16, p = .31 in hip fracture patients. There was also
a significant association between GDS scores and the-
frequency of PD1+ve CD4 T cells, r (41) = .34, p = .02
[Figure 6c]. Interestingly, a significant association was
found between circulating IL6 levels and the frequency
of senescent CD57+ve CD4 T cells, r (63) = .39, p = .04
[Figure 6d], such that patients with higher serum levels of
IL6 had a higher frequency of circulating CD57+ve CD4 T
cells.
Cortisol and T cell phenotype
Cortisol is known to induce apoptosis in T cells, therefore
we determined whether there was an association between
serum cortisol levels and T cell numbers. However, no
association was observed between serum cortisol levels
and frequency of circulating T cells (β = −.17, p = .18,
ΔR2 = .03), absolute T cell numbers (β = −.20, p = .27,
ΔR2 = .04), frequency of activated CD69+ve CD8 T cells
(β = .16, p = .22, ΔR2 = .02), HLADR+ve CD8 T cells
(β = .22, p = .11, ΔR2 = .04), senescent CD28-ve CD8 T
cells (β = − .04, p = .72, ΔR2 = .002), CD57+ve CD8 T cells
(β = − .04, p = .74, ΔR2 = .002), KLRG1+ve CD8 T (β = .18,
Figure 4 (See legend on next page.)
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Figure 4 Frequency of peripheral activated T lymphocytes in hip fracture patients with and without depressive symptoms versus
healthy controls. (a) Representative flow cytometry plots showing frequency of CD69+ve CD8 T cells in a healthy control, hip fracture and a
hip fracture patient with depressive symptoms. (b) The percentage of CD69+ve CD4 and CD8 T cells in healthy controls: n = 21 (open bars); hip
fracture patients without depression: n = 22 (grey bars) and hip fracture patients with depressive symptoms: n = 24 (black bars). (c) Representative
flow cytometry plots showing frequency of HLADR+ve CD8 T cells in a healthy control, hip fracture and a hip fracture patient with depressive
symptoms. (d) The percentage of HLADR+ve CD4 and CD8 T cells in healthy controls: n = 21 (open bars); hip fracture patients without depression:
n = 22 (grey bars) and hip fracture patients with depressive symptoms: n = 24 (black bars). Data are mean ± SEM. *p < .01 and **p < .001.
Duggal et al. Immunity & Ageing  (2014) 11:25 Page 10 of 16p = .20, ΔR2 = .03), PD1+ve CD4 T cells (β = .07, p = .62,
ΔR2 = .005), or PD1+ve CD8 T cells (β = .28, p = .07,
ΔR2 = .09) in hip fracture patients.
Cytokines and T cell phenotype
A significant association was found between circulating
IL6 levels and the frequency of senescent CD28-ve CD57+ve
T cells, β = .37, p = .01, ΔR2 = .13, such that patients with
higher serum levels of IL6 had a higher frequency of
circulating CD28-ve CD57+ve T cells [Additional file 1:
Figure S2a]. A similar association was observed between
serum TNFα levels and the frequency of CD28-ve CD57+ve T
cells, β= .44, p = .01, ΔR2 = .19 [Additional file 1: Figure S2b].
Discussion
Depression is a common public health problem that has
been identified by the World Health Organisation as a
leading cause of disability worldwide [39]. Depression in
addition to being a psychiatric disorder has also been as-
sociated with a state of immune dysfunction [40]. In the
present study, we have reported that new onset depres-
sion results in both phenotypic and functional alteration
in peripheral T cells in elderly hip fracture patients.
Firstly, we report a decline in T cell frequency and ab-
solute numbers in hip fracture patients with depressive
symptoms compared with healthy controls, which is in
agreement with previous reports of reduced circulating
T cells in depressed individuals [41,42]. Although the
exact mechanism responsible has not been explored in
this manuscript, a few possibilities can be proposed. Ex-
posure to chronic stress is accompanied by increased
HPA axis activity [43,44]. Glucocorticoids are known in-
ducers of T cell apoptosis [45]. We have previously re-
ported elevated serum cortisol levels in hip fracture
patients with depressive symptoms [31]. However, there
was no association between circulating T cell numbers
and serum cortisol levels, suggesting that additional
mechanisms may be responsible for the reduction in cir-
culating T cells in hip fracture patients with depressive
symptoms.
Evaluation of T cell subsets revealed that the propor-
tion of CD4 and CD8 T cells and the CD4:CD8 ratio did
not differ between hip fracture patients with and without
depressive symptoms and healthy controls. These fin-
dings are in line with previous reports showing that theCD4:CD8 ratio was unaltered in depressed individuals
[46,47]. Furthermore, hip fracture alone or in synergy
with depressive symptoms did not have an effect on the
naïve: memory ratio of T cells suggesting that this stress
did not further exacerbate the age-related decline in
naive T cells or expansion of the memory T cell pool.
These findings contradict a previous study reporting an
increase in memory T cells in depressed patients [48,49].
This discrepancy might be due to the differences in cell
surface markers used to identify memory T cells as Maes
et al. identified memory T cells as CD45RA-ve T cells,
whereas in this study both CD45RA and CCR7 were
used to identify T cell subsets. In addition our patients
did not suffer from chronic depression and their condi-
tion was acute in response to their injury.
It is well documented that ageing is accompanied by
an accumulation of senescent T cells. On examining the
additional effect of chronic stress on CD28 expression, a
significant increase in the percentage of CD28-ve T cells
was seen, especially in CD8 T cells in hip fracture pa-
tients with depressive symptoms. Moreover, an increase
in CD57+ve T cells, again most marked in CD8 T cells,
was also observed in hip fracture patients with depres-
sive symptoms, which is in line with previous studies in
depressed individuals [49]. Interestingly, poor mental
health associated with reduced job satisfaction has also
been characterised by an increase in CD57+ve CD8 T
cells [50]. The majority of the CD57+ve T cells are also
CD28-ve[51], therefore it is not surprising that an accu-
mulation of CD28-veCD57+ve T cells was seen in hip frac-
ture patients with depressive symptoms and this is in
agreement with similar findings in depressed individuals
[52]. The accumulation of these expanded T cells could
reduce the T cell repertoire in hip fracture patients with
new onset of depression and reduce their immune re-
sponse towards novel pathogens and vaccines [53,54].
Although the exact mechanism responsible for accu-
mulation of senescent T cells has not been explored in
this manuscript, a few possibilities can be proposed.
TNFα is known to induce down regulation of CD28
expression on T cells [55]. In this study we found a cor-
relation between circulating CD28-ve CD57+ve T cells
and serum IL6 and TNFα levels, suggesting the contri-
bution of the pro-inflammatory environment in accumu-
lation of senescent T cells. Further, CMV seropositivity
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Figure 5 Cytokine production by T lymphocytes in hip fracture patients. (a) The Th1 (IFNγ+ve) / Th2 (IL4+ve) ratio, or (b) the percentage of
IL17+ve CD4 T cells in healthy controls, n = 16; hip fracture patients without depression (HF), n = 21; and hip fracture patients with depressive
symptoms (HF + D), n = 21. The solid bar represents the mean value. (c) Representative flow cytometry plots showing frequency of IL6+ve CD4
(upper panel) and TNFα+ve T cells (lower panel) in a healthy control, hip fracture and a hip fracture patient with depressive symptoms. (d) The
percentage of IL6+ve CD4 T cells or (e) TNFα+ve T cells in healthy controls, n = 16; hip fracture patients without depression (HF), n = 23; and hip
fracture patients with depressive symptoms (HF + D), n = 22. The solid bar represents the mean value. The solid bar represents the mean value.
*p < .05 and **p < .01.
Duggal et al. Immunity & Ageing  (2014) 11:25 Page 11 of 16has also been associated with senescence in the T cell com-
partment and accumulation of late differentiated CD28-ve
CD57+ve T cells [56,57]. Although, CMV seropositivity has
not been tested in our hip fracture patients, it is possiblethat there might be an association between CMV and ac-
cumulation of senescent T cells in hip fracture patients.
In addition to being an inflammatory disorder, depres-
sion is also characterised by activation of cell-mediated
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Figure 6 Association between senescent T cells and depressive symptom score (GDS) and circulating pro-inflammatory cytokine IL6.
Correlation between (a) GDS score and circulating CD57+ve CD4 T cells (n = 41), (b) GDS score and circulating CD28-ve CD8 T cells (n = 37),
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monocyte activation in hip fracture patients with depres-
sive symptoms [59], an increase in T cells expressing the
activation markers CD69 and HLADR was seen in hip
fracture patients with depressive symptoms. These fin-
dings are consistent with previous reports of increased
activated HLADR+ve T cells in depressed individuals
[48,60,61]. Overall, our data point towards the existence
of a state of immune activation in individuals with de-
pressive symptoms.
Next, on exploring T cell functional properties in hip
fracture patients we found no significant differences in
Th1 (IFNγ)/Th2 (IL4) balance between our hip fracture
patients with and without depression. Previous findings
have associated depressed mood [62] with a shift in the
Th1/Th2 balance towards a Th2 response, in this study
we did observe a trend towards an increase in Th2 cells
(IL4+ve CD4 T cells) but it did not reach statistical sig-
nificance. Ageing is also accompanied by a skewing to-
wards a Th17 phenotype [63] and a similar increase in
Th17 cells has been reported in patients with major de-
pressive symptoms [64]. However, in this study no such
increase in Th17 producing CD4 T cells was observed in
hip fracture patients with depressive symptoms post
stimulation.
Depression has been characterised as an increased in-
flammatory status (inflammaging) including elevatedlevels of pro-inflammatory cytokines, including IL6, TNFα
and IL1β [65,66]. We have previously reported that ele-
vated levels of TNFα and IL6 were seen in hip fracture pa-
tients with depressive symptoms compared with patients
without depressive symptoms and healthy controls [31].
On examining pro-inflammatory cytokine production by
T cells, we found that hip fracture patients with depres-
sive symptoms had a higher capacity to produce pro-
inflammatory cytokines upon stimulation. Our findings
are consistent with the reports of elevated IL6 produc-
tion post-stimulation in depressed patients [67]. These
findings are also in line with previous reports of ele-
vated TNFα production by peripheral blood mono-
nuclear cells in depressed patients [68].
Conclusions
The present study reports for the first time that develop-
ment of depressive symptoms in older hip fracture pa-
tients can result in phenotypic alteration in T cells and
dysregulated cytokine production. Importantly, these
findings suggest that development of depressive symp-
toms after a hip fracture in older adults is an important
driver of immune dysregulation. The clinical significance
of these results still remains unexplored, but our fin-
dings support the need for preventing and treating de-
pression and depressive symptoms to improve outcomes
in older hip fracture patients.
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Participants
101 older hip fracture patients (37 male) were recruited
from five hospitals in Birmingham, UK between 2010
and 2012. Inclusion criteria were that participants had to
be aged 60 years and over with a hip fracture sustained
4–6 weeks previously but with no chronic immune-
related disorders e.g., cancer, diabetes, or taking any
regular medications that might modify immunity, e.g.,
immunosuppressants, statins. Additionally patients must
not have had any diagnosis of depression by a physician
prior to age 50 years or be taking or have previously
taken anti-depressant medication. 43 healthy older adults
(26 female), were also recruited from the community as
controls. The study was approved by South Birmingham
Local Research Ethics Committee and all participants pro-
vided written informed consent (study ref: 09/H1203/80).
Study design
The study design and patient demographics have been
reported in full previously [69]. Briefly, the study was a
prospective case–control design with three groups of
older adults: hip fracture patients with or without de-
pressive symptoms and healthy older adults. Consent
was gained whilst patients were still in hospital. All pa-
tients provided a blood sample and completed question-
naires and structured interviews 4–6 weeks after hip
fracture. Control participants attended the University to
provide a single blood sample and complete a depression
and anxiety symptoms scale questionnaire and provide
basic demographic information. Blood samples were ta-
ken between 09.00 and 11.00 to minimise any effect of
diurnal variations in steroid or cytokine levels. None
of the participants had an acute infection at the time of
blood sampling.
Questionnaires
Standard socio-demographic and health behaviour infor-
mation were taken and medications, prescription and
over-the-counter, were recorded by the interviewer. The
psychological status of the participant was assessed by
means of standardised psychometric questionnaires. De-
pression was evaluated by a Geriatric Depression Scale
(GDS) [70]. Depression was defined as a GDS score
greater than or equal to 6. The Hospital Anxiety and
Depression Scale (HADS) was also used to measure
depression and anxiety [71]. The scale contains 14 items,
scored from 0 (not present) to 3 (considerable), with
seven assessing aspects of depression and seven asses-
sing anxiety. Healthy control participants completed the
HADS depression sub-scale in order to check that they
did not have significant depressive symptoms. A cut-off
of ≥8 has previously been used to indicate possible de-
pression [72].Isolation of PBMCs and immunostaining for analysis of
T cell subsets
PBMCs were isolated from peripheral blood by density
centrifugation using Ficoll-Paque™ PLUS (GE Healthcare,
Uppsala, Sweden). The blood was layered on top of 6 ml
Ficoll in a 25 ml universal tube and centrifuged at 650 × g
for 30 minutes with no break. Post centrifugation, the
mononuclear cell layer containing PBMC was removed
and added to a new universal tube and the cells were
washed twice with PBS and counted using a haemocy-
tometer. PBMCs were frozen down by re-suspending cells
in freezing medium consisting of 10% DMSO (Sigma
Aldrich, UK) in heat inactivated fetal calf serum (Biosera,
UK) and transferring them in small aliquots into cryovials.
The cryovials were transferred into a freezing container
(Mr Frosty, Sigma Aldrich, UK) containing isopropanol
(VWR International, UK) and the frozen cells were then
stored at −80°C.
For phenotypic characterisation of T cells, isolated
PBMCs were stained with a combination of fluorochrome
conjugated antibodies including; anti-human CD3-PEcy7
(eBiosciences; clone:UCHT1), anti-human CD4 Alexa
fluor 450 (Biolegend; clone:RPA-T4), anti-human CD8 PE
(Immunotools; clone:UCHT4), anti-human CCR7 FITC
(Rand D systems; clone:150503) anti-human CD45RA
APC (Biolegend; clone:HI-100), anti-human CD28-APC
(BD biosciences; clone:CD28.2), anti-human CD57-FITC
(eBiosciences; clone:HDC57), anti-human CD69-FITC (eBios-
ciences; clone:FN50), anti-human CD25-APC (eBiosciences;
clone:BC96), anti-human HLADR-FITC (eBiosciences; clone:
H1.2 F3), anti-human KLRG1-FITC (Biolegend; clone:2
F1/KLRG1), anti-human CD279-APC (eBiosciences;
clone:eBioJ105). Appropriate isotype controls were used
for setting gates. Following incubation, cells were washed
and resuspended in PBS for flow cytometric analysis using
a Cyan™ ADP flow cytometer (Dako). T cells can be clas-
sified into four distinct subsets on the basis of expres-
sion of cell surface markers, CCR7 and CD45RA; naïve
(CD45RA+ve CCR7+ve), central memory (CD45RA-ve
CCR7+ve), effector memory (CD45RA-ve CCR7-ve) and
effector memory RA (CD45RA-ve CCR7–ve) [32]. The
gating strategy used to identify T cell subsets is shown in
Figure 1c-f.
In-vitro cultures of PBMCs to induce cytokine production
by T cells
PBMC cultures were performed in complete RPMI 1640
(Sigma Aldrich, UK) containing 10% FCS (Biosera, UK)
supplemented with glutamine/penicillin/streptomycin
(Life Technologies, UK). PBMCs were stimulated for
4 hr with PMA (50 ng/ml; Sigma Aldrich, UK) and
Ionomycin (500 ng/ml; Sigma Aldrich, UK) in the pre-
sence of Brefeldin A (10 μg/ml; Sigma Aldrich, UK).
Post-stimulation, cells were washed twice with PBS and
Duggal et al. Immunity & Ageing  (2014) 11:25 Page 14 of 16stained using anti-human CD3 PEcy7 (eBiosciences,
UK; clone: UCHT1) and anti-human CD4 Alexa fluor 450
(eBiosciences, UK; clone: RPA-T4) for 20 min in the dark
at 4°C. Cells were washed and fixed with 50 μl Reagent A
(Fix and Perm kit, Invitrogen, UK) for 30 minutes in the
dark at room temperature. Post incubation, cells were
washed and re-suspended in 50 μl Reagent B (Fix and
Perm kit, Invitrogen, UK) and anti-human TNFα PE
(eBiosciences, UK; clone: MAb11) or anti-human IL6
APC (eBiosciences, UK; clone: MQ213A5) or anti-human
IL17A Alexa fluor 647 (Biolegend, UK; clone:ebio64-
Dec13) or anti-human IFNγ APC (Bio legend, UK ;clone:
AS.B3) and anti-human IL4 PE (eBiosciences, UK;
clone:8D4-8) was added and samples were incubated in
the dark at room temperature for 30 minutes. After
washing the cells were analysed on a Cyan™ ADP (Dako
Ltd, UK).Serum cytokines and cortisol
Serum IL-6 and TNFα were measured using multiplex
technology and a commercial 5-plex kit (BioRad, Hemel
Hempstead, UK). Serum cortisol was measured using
a commercial ELISA kit (IBL international, Hamburg,
Germany).Statistical analysis
Univariate ANOVA with least significant difference post-
hoc tests were used to assess differences between the three
groups (hip fracture with depressive symptoms, hip frac-
ture without depressive symptoms, and healthy controls).
Where demographic variables differed significantly bet-
ween the three groups, analyses were rerun adjusting for
these variables using ANCOVA. Pearson’s correlations
were used to examine associations between depression
score/serum hormone levels/circulating cytokine levels
and T cell phenotype and cytokine production.Additional file
Additional file 1: Figure S1. CD28-ve CD57+ve T lymphocytes in hip
fracture patients. Percentage of (a) CD28-veCD57+ve CD4 T cells, or
(b) CD28-veCD57+ve CD8 T cells in healthy controls (n = 23), hip fracture
patients without depressive symptoms (HF; n = 19) and hip fracture
patients without depressive symptoms (HF + D; n = 17). The solid bar
represents the mean value. *p <.05. Figure S2. Association between
circulating pro-inflammatory cytokines and senescent T cells. Correlation
between (a) serum IL6 levels and the frequency of circulating CD28-ve
CD57+ve T cells (n = 44) (b) serum TNFα levels and frequency of circulating
CD28-ve CD57+ve T cells (n = 29).Competing interests
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